NCT07911995
A Trial to Investigate the Efficacy and Safety of Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular Dystrophy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Start date pushed from Nov 9, 2026 to Nov 30, 2026
- Secondary endpoints: 17 to 4
- Study title shortened, about 5 words
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Core Phase: Change From Baseline in Time-to-Stand-from-Supine (TTSTAND) Velocity
Timeframe: Baseline to Week 24
Extension Phase: Incidence of Adverse Events
Timeframe: First dose through Week 96
Secondary (4)
Core Phase: Change From Baseline in Stride Velocity 95th Centile (SV95C)
Core Phase: Change From Baseline in 10-Meter Walk/Run (10MWR) velocity
Core Phase: Change From Baseline in Time-to-Climb-4-Stairs (TTCLIMB) velocity
Core Phase: Incidence of Adverse Events
Arms and interventions
Tegacorat Low doseExperimental
Tegacorat Treatment Group 1
Tegacorat Mid DoseExperimental
Tegacorat Treatment Group 2
Tegacorat High doseExperimental
Tegacorat Treatment Group 3
Drugs: Tegacorat